Trial Profile
A Deep Phenotyping Approach to Assess the Effect of Uric Acid Lowering in Patients With Uncomplicated Type 1 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Febuxostat (Primary)
- Indications Hyperuricaemia
- Focus Therapeutic Use
- 11 Jan 2018 Status changed from recruiting to completed.
- 31 Jan 2015 New trial record